v3.26.1
Summary of Significant Accounting Policies (Tables)
 6 Months Ended
Jun. 30, 2026
Accounting Policies [Abstract]  
Schedules of Concentration of Credit Risk Customers that accounted for 10% or greater of accounts receivable, net as of June 30, 2026 and December 31, 2025 were as follows:
June 30,
2026		December 31,
2025
Customer A25%*
Customer B18%*
Customer C13%88%
Customer D12%*
Customer E10%*
*Accounts Receivable was less than 10%
Customers that accounted for equal to or greater than 10% of total revenue were as follows:
Six months ended
June 30,
20262025
Customer A51%26%
Customer B*16%
Customer C*12%
*Less than 10% of total revenue for the period
Schedule of Estimated Fair Value of Convertible Notes Payable Assumptions
The Company calculated the estimated fair value of the convertible notes payable using the following assumptions. No convertible notes were issued during the six months ended June 30, 2026. Accordingly, there were no assumptions used in the determination of fair value for that period.
Six months ended
June 30, 2025
Issuance date2/10/2025
Maturity date5/10/2026
Stock price
5.88 - 7.45
Expected volatility factor
124.8 - 128.3%
Risk-free interest rate
4.02 - 4.25%
Schedules of Changes in Convertible Notes Payable Measured at Fair Value
The following table presents changes in the Level 3 convertible notes payable measured at fair value for the six months ended June 30, 2025 and June 30, 2026 (in thousands):
Balance, January 1, 2025$— 
Additions14,433 
Fair value measurement adjustments6,864 
Loss on extinguishment4,623 
Redemption(1,650)
Conversion into common stock(4,836)
Balance, June 30, 2025$19,434 
Balance, January 1, 2026$4,518 
Fair value measurement adjustments867 
Gain on extinguishment(326)
Conversion into common stock(5,059)
Balance, June 30, 2026$— 
Schedules of Revenue Disaggregated by Revenue Type
The following table presents the Company’s revenue disaggregated by revenue type (in thousands):
Three months ended
June 30,		Six months ended
June 30,
2026202520262025
Product related$19,712 $2,091 $34,923 $3,720 
Contract related477 1,128 737 1,128 
Total$20,189 $3,219 $35,660 $4,848 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Outstanding securities not included in the computation of diluted net loss per share because their effect would have been anti-dilutive include:
June 30,
2026		December
31, 2025
Series B Preferred Stock, as converted4 4 
Stock options4,909 4,701 
Warrants5 583 
Restricted stock2,165 2,124 
Total7,083 7,412